Diagnostic Criteria for MASH
Liver biopsy remains the definitive diagnostic method for MASH, requiring histological evidence of hepatic steatosis, lobular inflammation, and hepatocellular ballooning in a characteristic pattern. 1, 2
Histological Requirements
The diagnosis of MASH requires all three microscopic features on liver biopsy:
- Hepatic steatosis (fat accumulation in hepatocytes)
- Lobular inflammation (inflammatory cell infiltrates within liver lobules)
- Hepatocellular ballooning (hepatocyte injury with cell swelling)
These features must occur in a characteristic distribution pattern, typically with a NAFLD Activity Score (NAS) ≥4. 1, 3
Clinical Context Required
MASH diagnosis also requires the presence of metabolic dysfunction, defined by at least one of the following cardiometabolic risk factors:
- Type 2 diabetes or prediabetes
- Abdominal obesity (elevated waist circumference)
- Hypertension
- Elevated plasma triglycerides
- Low HDL cholesterol
Alcohol consumption must be below harmful thresholds: <140 g/week for women (<2 standard drinks/day) and <210 g/week for men (<3 standard drinks/day). 4
Non-Invasive Assessment Limitations
No non-invasive method can definitively diagnose MASH because none can assess the critical microscopic features of ballooning and lobular inflammation. 1, 2 This is a crucial limitation acknowledged by the 2024 EASL-EASD-EASO guidelines with 96-100% consensus.
However, non-invasive tools serve important roles:
Blood Biomarkers
- Some scores (e.g., cytokeratin-18, NIS4, FAST score) may help identify individuals with MASH at risk of disease progression 1, 5
- These are useful for risk stratification but cannot replace biopsy for definitive diagnosis
Imaging Techniques
- MRI-based scores (e.g., MR-MASH score combining proton density fat fraction and waist circumference) show promise with AUC 0.86-0.88 for identifying MASH 6
- Elastography methods assess fibrosis but not steatohepatitis itself
When Biopsy Is Required
Liver biopsy is essential for:
- Definitive diagnosis of steatohepatitis 1, 2
- Clinical trial enrollment requiring NAS scoring 1
- Ruling out alternative liver diseases (e.g., autoimmune hepatitis) 1
- Confirming MASH when treatment decisions depend on histological confirmation
Liver biopsy may not be required for:
- Routine clinical management when fibrosis stage alone guides treatment decisions 1
- Patients where non-invasive risk stratification is sufficient for management
Practical Diagnostic Algorithm
For suspected MASH:
- Confirm hepatic steatosis via imaging (ultrasound, MRI, or CT)
- Verify metabolic dysfunction (≥1 cardiometabolic risk factor present)
- Exclude harmful alcohol use and other causes of steatosis
- Assess fibrosis risk using FIB-4, followed by elastography if indicated
- Consider liver biopsy when:
- Definitive MASH diagnosis needed for treatment decisions
- Enrolling in clinical trials
- Alternative diagnoses must be excluded
- Patient has high-risk features (type 2 diabetes, older age, elevated BMI) 7
The 2024 guidelines emphasize that while biopsy remains the gold standard for MASH diagnosis, most clinical management decisions can be made based on non-invasive fibrosis assessment combined with metabolic risk profiling. 1, 2